Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
109.8 USD | -0.15% | -1.23% | -10.69% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.69% | 6.93B | C+ | ||
+31.52% | 662B | C+ | ||
+21.96% | 546B | B | ||
-5.21% | 359B | C+ | ||
+17.02% | 323B | B- | ||
+5.01% | 289B | C+ | ||
+13.68% | 234B | B+ | ||
+3.81% | 198B | B- | ||
-10.63% | 194B | A+ | ||
+3.98% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JAZZ Stock
- Ratings Jazz Pharmaceuticals plc